SIGYN THERAPEUTICS INC - SIGY STOCK NEWS

Sigyn Therapeutics (OTC: SIGY) has progressed its Sigyn Therapy, aimed at treating sepsis, with significant milestones achieved in 2021. The company completed five in vitro blood purification studies demonstrating the therapy’s ability to address various pathogens, including COVID-19. Manufacturing enhancements allow greater efficiency, enabling up to seven bloodstream passes during treatment. A pilot animal study has been successfully completed, paving the way for potential human trials in 2022. The company is preparing an Investigational Device Exemption (IDE) for FDA submission to initiate these studies.

Sigyn Therapeutics, Inc. (OTC: SIGY), a medical technology company, is advancing its Sigyn Therapy, a dual-function blood purification system aimed at treating pathogen-related conditions, particularly in the context of sepsis. This technology targets a variety of viral pathogens and inflammatory mediators, including COVID-19. The company highlights the importance of blood purification devices in addressing severe infections, especially as pandemic threats continue. Sigyn Therapy is designed for use with existing hospital equipment, and aims to broaden its applications beyond infectious diseases.

Sigyn Therapeutics, Inc. (OTC: SIGY) announced promising preclinical results for its Sigyn Therapy, a dual-function blood purification technology. The therapy demonstrated the ability to significantly reduce gram-positive bacterial toxins in human blood plasma, crucial in treating sepsis—a leading cause of hospital deaths. With reductions of ~50% for peptidoglycan and ~70% for lipoteichoic acid within two hours, the results support the technology's potential. Sigyn Therapy targets a range of pathogen-associated illnesses, including drug-resistant infections and community-acquired pneumonia.

Sigyn Therapeutics, Inc. (OTC Markets: SIGY) announced an interview with CEO Jim Joyce on Tech Nation, discussing their innovative Sigyn Therapy. This therapy aims to treat life-threatening inflammatory conditions caused by cytokine storm syndrome, a critical issue during the COVID-19 pandemic. Joyce highlighted the device's dual function: eliminating inflammatory cytokines and targeting their sources, like viral pathogens. The potential market opportunity exceeds $20 billion, positioning Sigyn Therapy as pivotal in addressing severe health concerns.

Sigyn Therapeutics (OTC Markets: SIGY) announced its continued development of Sigyn Therapy, aimed at treating sepsis and inflammatory conditions. The therapy exhibits capabilities to target a broad range of inflammatory agents, including viral pathogens and cytokines. The technology features over 170,000 square meters of surface area for adsorption, significantly more than its competitors. The company is preparing an Investigational Device Exemption (IDE) to initiate human clinical studies, building on positive results from prior animal studies. The potential market exceeds $20 billion.

Sigyn Therapeutics (OTC: SIGY) announced the successful completion of a pilot animal study validating its Sigyn Therapy™ for treating life-threatening inflammatory conditions. This marks the first use of the therapy in mammals, demonstrating safe administration without complications over six-hour treatment periods. Sigyn Therapy aims to capture a market exceeding $20 billion annually, specifically targeting conditions like sepsis. Following positive outcomes, the company plans additional studies and seeks FDA clearance to initiate human trials.

Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) announced the completion of a study demonstrating the effectiveness of Sigyn Therapy™ in eliminating hepatic toxins like bile acid, bilirubin, and ammonia from human blood plasma. Results showed an 80.6% reduction of bile acid and 55% reduction of bilirubin in one hour. The therapy targets life-threatening inflammatory conditions, especially hepatic encephalopathy, which can have a 30-day mortality rate of 38% in severe cases. The company plans to submit an Investigational Device Exemption to the FDA by year-end 2021.

Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) has completed an in vitro blood purification study, validating that Sigyn Therapy can eliminate toxins associated with Hepatic Encephalopathy, a severe neurological condition. The therapy showed a 55% reduction in bilirubin levels in just one hour and 69.5% over four hours. This innovative technology addresses the significant unmet need for life-threatening inflammatory conditions. Sigyn plans to submit data for an Investigational Device Exemption to the FDA by year-end 2021, potentially expanding its market presence valued at over $20 billion.

Sigyn Therapeutics announced a webinar scheduled for June 29, 2021, at 12 PM Eastern, featuring Chairman and CEO, Jim Joyce. The webinar will cover the evolution of blood purification technologies in response to pandemic threats, including COVID-19. Joyce will discuss the significance of blood purification therapies in treating life-threatening conditions, particularly those caused by Cytokine Storm Syndrome. The company aims to address a $20 billion market opportunity with its Sigyn Therapy, designed to mitigate inflammatory conditions like sepsis.